Uh-oh! This study is no longer available.
Invasive Urothelial Carcinoma – Post-Surgery Treatment
PMG Research of DuPage Medical Group
18 or older
A research study is evaluating whether an investigational medication may lower the chances of the bladder cancer to return in patients who have had surgery to remove invasive urothelial carcinoma.
This research study may be an option if you:
• Have a diagnosis of invasive urothelial carcinoma
• Have FGFR3 Alterations
• Had nephroureterectomy, distal ureterectomy, or cystectomy within 120 days
Additional inclusion and exclusion criteria apply. Patients must meet all eligibility criteria to be considered for the clinical research study.
Qualified participants will receive study medication or placebo at no cost. You will not be required to pay for any study related procedures. You or your insurance company may be billed for any other health care costs, including those standard of care procedures that you receive while participating in the study.
Patient Commitment Duration
Dependent on disease status (such as recurrence
Financial compensation may be provided for travel expenses.
Number of visits in study
Dependent on the length of participation in the study